Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of trilaciclib versus placebo for myeloprotection during concurrent chemoradiotherapy in limited-stage small cell lung cancer
CTR20262087Phase 3Active
- Sponsor
- Simcere Zaiming Pharmaceutical
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trilaciclib in small cell lung cancer (SCLC), sponsored by Simcere Zaiming Pharmaceutical. Started Jun 2026; status: active.
02
Drugs
trilaciclib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20262087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262087.